Linked Life Data

14512295

Source:http://linkedlifedata.com/resource/pubmed/id/14512295

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2004-1-2
pubmed:abstractText
The optimal induction for older adults with acute myeloid leukemia (AML) is unknown. Several anthracyclines have been proposed, but the data remain equivocal. Additionally, few prospective trials of priming with hematopoietic growth factors to cycle leukemia cells prior to induction chemotherapy have been conducted. Three hundred and sixty-two older adults with previously untreated AML were randomized to either daunorubicin, idarubicin or mitoxantrone with a standard dose of cytarabine as induction therapy. In addition, 245 patients were also randomized to receive granulocyte-macrophage colony-stimulating factor (GM-CSF) or placebo beginning 2 days prior to induction chemotherapy and continuing until marrow aplasia. No difference was observed in the disease-free overall survival or in toxicity among patients receiving any of the 3 induction regimens or among those receiving growth factor or placebo for priming. However, the complete remission rate for the first 113 analyzable patients, who did not participate in the priming study and started induction therapy 3 to 5 days earlier than those who did, was significantly higher (50% versus 38%; P =.03). None of the anthracyclines is associated with improved outcome in older adults. Priming with hematopoietic growth factor did not improve response when compared with placebo. Furthermore, delaying induction therapy in older adults may lead to a lower complete remission rate.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0006-4971
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
103
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
479-85
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:14512295-Aged, pubmed-meshheading:14512295-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:14512295-Chromosome Aberrations, pubmed-meshheading:14512295-Chronic Disease, pubmed-meshheading:14512295-Cytarabine, pubmed-meshheading:14512295-Cytogenetics, pubmed-meshheading:14512295-Disease-Free Survival, pubmed-meshheading:14512295-Drug Administration Schedule, pubmed-meshheading:14512295-Female, pubmed-meshheading:14512295-Granulocyte-Macrophage Colony-Stimulating Factor, pubmed-meshheading:14512295-Humans, pubmed-meshheading:14512295-Leukemia, Myeloid, pubmed-meshheading:14512295-Male, pubmed-meshheading:14512295-Middle Aged, pubmed-meshheading:14512295-Recombinant Proteins, pubmed-meshheading:14512295-Survival Analysis, pubmed-meshheading:14512295-Time Factors
pubmed:year
2004
pubmed:articleTitle
A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group.
pubmed:affiliation
Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center and Technion, Haifa 31096 Israel. rowe@jimmy.harvard.edu
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Research Support, U.S. Gov't, P.H.S., Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase III